Goldman Sachs
CLRB icon

Goldman Sachs’s Cellectar Biosciences CLRB Stock Holding History

Goldman Sachs’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-360
Closed -$3.41K – 6116
2025
Q1 		$3.41K Sell
360
-1,055
-75% -$9.55K ﹤0.01% 5997
2024
Q4 		$12.7K Buy
1,415
+731
+107% +$33.8K ﹤0.01% 5925
2024
Q3 		$43.9K Sell
684
-483
-41% -$31.9K ﹤0.01% 5642
2024
Q2 		$87.5K Buy
+1,167
New +$112K ﹤0.01% 5413
2016
Q1 		– Sell
-1
Closed -$16K – 7101
2015
Q4 		$16K Hold
1
– – ﹤0.01% 6889
2015
Q3 		$50K Hold
1
– – ﹤0.01% 6785
2015
Q2 		$79K Hold
1
– – ﹤0.01% 6716
2015
Q1 		$74K Sell
1
-1
-50% -$80.3K ﹤0.01% 6558
2014
Q4 		$193K Buy
+2
New +$154K ﹤0.01% 6184

Other funds holding CLRB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
RCA
Riverview Capital Advisers Boston, Massachusetts $300M AUM 10.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Goldman Sachs's CLRB Position: Q2 2025 in Review

Goldman Sachs sold out of Cellectar Biosciences (CLRB) in Q2 2025, closing a stake of 360 shares — an estimated $3.41K sold.

Goldman Sachs first reported a position in CLRB in Q4 2014 and held it in 9 quarters. The position peaked at $193K in Q4 2014. 19 funds tracked by Wall St. Rank hold CLRB as of Q2 2025.

  • Goldman Sachs reported no remaining Cellectar Biosciences position as of Q2 2025 after selling out during the quarter.
  • Goldman Sachs sold 360 Cellectar Biosciences shares in Q2 2025, an estimated $3.41K.
  • Goldman Sachs first reported a position in Cellectar Biosciences in Q4 2014 and held it in 9 quarters.
  • Goldman Sachs's Cellectar Biosciences position peaked at $193K in Q4 2014.
  • 19 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q2 2025.

Based on Goldman Sachs's 13F filing for Q2 2025, filed 14 Aug 2025.